Global Outlook for Schizophrenia Medication Market grow potential, Analysis and Prediction 2024-2030
The schizophrenia drug market is poised for substantial expansion over the next decade, driven by a combination of technological advancements, increasing global prevalence of the disorder, and a growing focus on addressing stigma and improving long-term treatment outcomes.
According to Renub Research, a market research and information analysis company with over 14 years of experience, the schizophrenia market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.89% by 2030. This growth is expected to be fuelled by pharmaceutical companies' efforts to develop next-generation drugs.
Approximately 20 million people worldwide suffer from schizophrenia, with the 7 major markets accounting for over 6 million prevalent cases in 2022. The U.S. holds about 45%, EU4 and UK about 37%, and Japan about 18% of these cases.
One of the key drivers of market growth is the development of innovative therapies. KarXT (xanomeline-trospium) and cariprazine are gaining attention for their potential to treat schizophrenia with fewer side effects than traditional antipsychotics. KarXT is a novel muscarinic receptor agonist-antagonist combination, while cariprazine is an atypical antipsychotic already approved for use in schizophrenia and bipolar disorder.
Other promising pipeline drugs include iclepertin, brilaroxazine, and SEP-363856, which target different pathways of schizophrenia pathology to improve efficacy and tolerability. Long-acting injectable antipsychotics like Abilify Maintena (aripiprazole extended-release injectable) also remain popular due to improved adherence and consistent drug delivery.
The broader central nervous system (CNS) therapeutics market, which includes schizophrenia drugs, is also rising due to aging populations and increasing neurological disorder prevalence. The market is forecasted to reach around $156.5 billion by 2030, reflecting robust demand across neurological and psychiatric disorders.
The schizophrenia drug market is expected to see significant revenue growth by 2030, driven by the introduction of these innovative therapies and expanding patient populations. For those interested in more detailed insights, Renub Research has published the "Schizophrenia Drugs Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030" report, which includes enterprise analysis and market percentage records.
For more information, contact Rajat Gupta, Marketing Manager at Renub Research, at [email protected] or +1-478-202-3244 (USA) or +91-120-421-9822 (IND). You can also visit Renub Research's LinkedIn page (https://linkedin.com/company/renub-research) or website (www.renub.com) for more information.
Renub Research supports many blue-chip companies with findings and perspectives across various markets, and has published over 7000 syndicated reports and worked on over 500 custom research projects. The company's address is 225 Kristie Ln, Roswell, GA 30076.
In addition, the injectable treatment segment is experiencing the most rapid market growth in the Schizophrenia Drugs Market. China schizophrenia drugs market is a growing market with significant potential, impacting approximately 8.5 million individuals according to the World Health Organization.
Governments globally are proactively addressing schizophrenia prevention by promoting mental fitness, reducing substance abuse, and offering early intellectual health intervention. Retail pharmacies have secured a larger share in the Schizophrenia Drugs Market due to their accessibility and patient convenience.
Lastly, it's important to note that the Cancer Immunotherapy Market is expected to surpass around US$ 188.11 Billion by 2030. The Schizophrenia Drug Market has been covered from three viewpoints: Second Generation, Third Generation, and Others. The global schizophrenia drugs market serves a worldwide population of approximately 21 million individuals with intense mental disorders, as per the World Health Organisation.
In conclusion, the schizophrenia drug market is evolving rapidly with novel treatments like KarXT and cariprazine reshaping therapeutic approaches, supported by a strong industry growth trajectory expected to reach high double-digit CAGR rates through 2030. This progress is complemented by societal shifts toward better mental health awareness and integrated care models.
The growing focus on mental health and wellness, coupled with the advancements in science and technology, is driving the expansion of the schizophrenia drug market. In particular, new treatments like KarXT and cariprazine, which promise fewer side effects, are playing a significant role in this growth. Moreover, the rising demand for long-term treatment and better outcomes in health-and-wellness sectors is further fueling the market's development.
